Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers

BACKGROUND: Burkitt lymphoma (BL) is a rare, highly aggressive B-cell malignancy treated most successfully with brief-duration, high-intensity chemotherapeutic regimens. The benefit of the addition of rituximab to these regimens remains uncertain. We sought to examine the effectiveness of chemothera...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Wildes, Tanya M., Farrington, Laura, Yeung, Cecilia, Harrington, Alexandra M., Foyil, Kelley V., Liu, Jingxia, Kreisel, Friederike, Bartlett, Nancy L., Fenske, Timothy S.
Формат: Artigo
Язык:Inglês
Опубликовано: SAGE Publications 2014
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3891289/
https://ncbi.nlm.nih.gov/pubmed/24490019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620713514682
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы